Stockscreener 앱 받기
27.58
5.87%
1.5296
전일 마감가:
$26.05
열려 있는:
$26.13
하루 거래량:
412.90K
Relative Volume:
0.26
시가총액:
$1.25B
수익:
-
순이익/손실:
$-97.22M
주가수익비율:
-12.59
EPS:
-2.19
순현금흐름:
$-82.44M
1주 성능:
+5.51%
1개월 성능:
-4.50%
6개월 성능:
+23.84%
1년 성능:
+23.62%
1일 변동 폭
$26.03
$27.66
1주일 범위
$25.46
$29.49
52주 변동 폭
$8.79
$42.20
카사바 Stock (SAVA) Company Profile
명칭
Cassava Sciences Inc
전화
512-501-2444
주소
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
SAVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| SAVA | 27.58 | 1.25B | 0 | -97.22M | -82.44M | -2.19 |
| VRTX | 448.08 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.19 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.24 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.02 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
카사바 Stock (SAVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-11-16 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-07-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
| 2021-04-27 | 개시 | B. Riley Securities | Buy |
| 2021-02-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-05-18 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-15 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-01-10 | 재확인 | Maxim Group | Buy |
모두보기
카사바 주식(SAVA)의 최신 뉴스
Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year? - MSN
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer - citybiz
Cassava Sciences, Inc. Appoints Freda Nassif as Chief Commercial Officer - Marketscreener.com
Cassava Sciences stock up on Alzheimer’s update (SAVA:NASDAQ) - Seeking Alpha
What Makes Cassava Sciences (SAVA) a New Buy Stock - MSN
A High-potential Bull Put Strategy on Cassava Sciences - MSN
A High-Potential Bull Put Strategy On Cassava Sciences - Barchart
Cassava Sciences Inc (SAVA-Q) QuotePress Release - The Globe and Mail
Anavex, Cassava Sciences, Panax Ginseng, And Long-Term Treatment Of Alzheimer's Disease - Seeking Alpha
How To Trade (SAVA) - Stock Traders Daily
Cassava Sciences, Inc. (NASDAQ:SAVA) Q3 2024 Earnings Call Transcript - Insider Monkey
Cassava Sciences (NASDAQ:SAVA) Issues Quarterly Earnings Results - MarketBeat
Cassava Sciences (NASDAQ:SAVA) Given "Buy" Rating at HC Wainwright - MarketBeat
Cassava Sciences Q3 2024 Earnings Preview - MSN
Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla? - Benzinga
Another U.S. biotech based on Chinese science - STAT
Cassava Sciences: With Almost Half The Float Shorted, Results Could Be Interesting - Seeking Alpha
Cassava Sciences nears Alzheimer's drug trial results By Investing.com - Investing.com Canada
Cassava Sciences’ Q3 2024: Financials and Alzheimer’s Trials Progress - TipRanks
Cassava Sciences: Pivotal Alzheimer’s Data May Push Stock Toward Book Value (SAVA) - Seeking Alpha
Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh (NASDAQ:SAVA) - Seeking Alpha
Looking At Cassava Sciences's Recent Unusual Options Activity - Benzinga
Cassava Sciences nears Alzheimer's drug trial results - Investing.com India
Cassava Sciences stock in focus after earnings (SAVA:NASDAQ) - Seeking Alpha
Cassava Sciences Reports Q3 2024 Financial and Operating Results - The Manila Times
Cassava Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cassava Sciences (NASDAQ:SAVA) Trading Down 5.8%Should You Sell? - MarketBeat
Unpacking the Latest Options Trading Trends in Cassava Sciences - Benzinga
Analysts Believe Cassava Sciences Now Has 300% Upside From Here - MSN
Cassava Sciences (SAVA) Scheduled to Post Earnings on Thursday - MarketBeat
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024 - GlobeNewswire
International Assets Investment Management LLC Makes New Investment in Cassava Sciences, Inc. (NASDAQ:SAVA) - MarketBeat
Institutions along with individual investors who hold considerable shares inCassava Sciences, Inc. (NASDAQ:SAVA) come under pressure; lose 6.7% of holdings value - Yahoo Finance
Long Term Trading Analysis for (SAVA) - Stock Traders Daily
HC Wainwright & Co. Upgrades Cassava Sciences (SAVA) - MSN
Cassava Sciences Options Trading: A Deep Dive into Market Sentiment - Benzinga
Institutions profited after Cassava Sciences, Inc.'s (NASDAQ:SAVA) market cap rose US$72m last week but individual investors profited the most - Simply Wall St
(SAVA) Proactive Strategies - Stock Traders Daily
Cassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The Edge - Insider Monkey
Cassava Sciences (NASDAQ:SAVA) Trading 5.1% HigherWhat's Next? - MarketBeat
HC Wainwright Comments on Cassava Sciences, Inc.'s FY2025 Earnings (NASDAQ:SAVA) - MarketBeat
카사바 (SAVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
카사바 주식 (SAVA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Barry Richard | Director |
Apr 23 '24 |
Option Exercise |
22.00 |
176,085 |
3,873,870 |
469,562 |
| Kupiec James William | Chief Medical Officer |
Apr 18 '24 |
Option Exercise |
22.00 |
1,500 |
33,000 |
4,000 |
| Schoen Eric | Chief Financial Officer |
Apr 17 '24 |
Option Exercise |
22.00 |
1,500 |
33,000 |
21,300 |
0.42%
0.16%
자본화:
|
볼륨(24시간):